IsoPlexis (company)

IsoPlexis (company)

IsoPlexis is a Branford, Connecticut-based healthcare company developing a cellular response analysis platform.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

January 2020
IsoPlexis raises a $20,000,000 series C round from Northpond Ventures.
September 2017
IsoPlexis raises a $13,500,000 series B round from Connecticut Innovations, Ironwood Capital, North Sound Ventures and Spring Mountain Capital.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
IsoPlexis Corporation funding round, September 2017
13,500,000
September 2017
4 Results
Results per page:
Page 1 of 1

SBA Awards

SBA Award
Agency
Award Type
Amount (USD)
Date Awarded
IsoPlexis SBIR Phase II Award, August 2017
SBIR
1,691,242
August 1, 2017
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
IsoPlexis
April 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- IsoPlexis has received the highly coveted Red Dot Award: Product Design 2021. The international jury has awarded the IsoSpark the "Red Dot"...
Conor Hale
January 11, 2021
FierceBiotech
As single-cell analysis technologies continue their rapid development--promising a cell's-eye view of protein interactions and signaling--IsoPlexis hopes to establish itself as a provider of next-generation biology tools with $135 million in new financing.
AlleyWatch
January 2, 2021
AlleyWatch
The Pulse of New York Tech
IsoPlexis
December 8, 2020
www.prnewswire.com:443
/PRNewswire/ -- IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay, will...
December 2, 2020
BioSpace
The Scientist Names IsoPlexis Single Cell Intracellular Proteome a Top 10 Innovation of 2020 - read this article along with other careers information, tips and advice on BioSpace
IsoPlexis
December 2, 2020
www.prnewswire.com:443
/PRNewswire/ -- IsoPlexis, the leader in single-cell functional proteomics, announced today that the Single-Cell Intracellular Proteome Chip, its...
IsoPlexis
November 25, 2020
www.prnewswire.com:443
/PRNewswire/ -- IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay, will...
November 12, 2020
BioSpace
IsoPlexis' Blood-Based Biomarker Predicts Response and Progression-Free Survival to a Novel IL-2 Agonist and Checkpoint Inhibitor Doublet Therapy in a Phase 2 Study of Metastatic Melanoma Patients - read this article along with other careers information, tips and advice on BioSpace
IsoPlexis
November 11, 2020
www.prnewswire.com:443
/PRNewswire/ -- IsoPlexis today announced the launch of their groundbreaking new systems for functional proteomics. With this launch, IsoPlexis adds the...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.